For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Macrogenics, Inc.

USPTO Granted Patents = 132

% Expired Patents = 25.8

CIPO Patents = 20

EPO Patents = 42

Trademarks = 6

Forward Citations = 2,219

Loading Chart...

Loading Chart...

66 inventors (with patents filed for the assignee):

Leslie Sydnor Johnson (90 out of 127 patents)

Ling Ling Huang (60 out of 63 patents)

Ezio Bonvini (42 out of 43 patents)

4. Scott Koenig (34 out of 58 patents)

5. Paul A Moore (34 out of 81 patents)

6. Kalpana Shah (20 out of 20 patents)

7. Nadine Tuaillon (18 out of 18 patents)

8. Jeffrey B Stavenhagen (14 out of 15 patents)

9. Deryk T Loo (13 out of 17 patents)

10. Liqin Liu (12 out of 12 patents)

11. Ross La Motte-Mohs (11 out of 11 patents)

12. Chia-Ying Kao Lam (11 out of 12 patents)

13. Christopher Rankin (11 out of 11 patents)

14. Francine Zhifen Chen (10 out of 14 patents)

15. Sergey Gorlatov (9 out of 9 patents)

Core Competencies:

PD-1 Binding

Bispecific Molecules

HER2/neu Antibodies

LAG-3 Binding

CD3 Binding

Tri-Specific Binding

Antibody Drug Conjugates

Combination Therapy

Covalent Diabodies

B7-H3 Antibodies

IL-23A Targeting

Fc Region Alterations

132 patents: Sort by Forward Citations

1. 12600779 - LAG-3-Binding Molecules and Methods of Use Thereof (2026-04-14),

2. 12534531 - PD-1-BINDING MOLECULES AND METHODS OF USE THEREOF (2026-01-27),

3. 12448448 - Anti-PD-1 antibodies and uses thereof (2025-10-21),

4. 12435155 - CD137 binding molecules and uses thereof (2025-10-07),

5. 12364756 - Pharmaceutical compositions of a PD-1 antibody and use of the same (2025-07-22),

6. 12173051 - Bispecific molecules comprising an HIV-1 envelope targeting arm (2024-12-24),

7. 12049501 - CD3-binding molecules capable of binding to human and non-human CD3 (2024-07-30),

8. 12024569 - HER2/neu-specific antibodies and methods of using same (2024-07-02),

9. 11942149 - Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof (2024-03-26),

10. 11884744 - Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof (2024-01-30),

11. 11858991 - LAG-3-binding molecules and methods of use thereof (2024-01-02),

12. 11840571 - Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 (2023-12-12),

13. 11820818 - Multi-chain polypeptide-containing tri-specific binding molecules (2023-11-21),

14. 11795226 - Bispecific CD16-binding molecules and their use in the treatment of disease (2023-10-24),

15. 11787871 - Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting (2023-10-17),

MacroGenics is a biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics. With a unique and proprietary suite of antibody technologies, MacroGenics aims to create next-generation medicines that improve patients' lives. They have a diverse pipeline of product candidates in various stages of development for the treatment of cancer, autoimmune disorders, infectious diseases, and immunology disorders. For more information about MacroGenics, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Macrogenics, Inc.

132 Patents

#3 in Rockville, MD

#25 in Maryland

#2,939 in US

#6,088 in the World

Rockville, MD, United States of America

Macrogenics, Inc.

Forward Citations = 2,219

66 inventors:

Leslie Sydnor Johnson (90 out of 127 patents)

Ling Ling Huang (60 out of 63 patents)

Ezio Bonvini (42 out of 43 patents)

4. Scott Koenig (34 out of 58 patents)

5. Paul A Moore (34 out of 81 patents)

Please report any incorrect information to [email protected]

Loading…